JB Chemicals & Pharmaceuticals Limited — Q3 FY26 earnings call

Call held 19 Jan 2026

Management summary

JB Chemicals & Pharmaceuticals Limited delivered a strong Q3 FY26, with revenues growing 11% to INR1,065 crore and net profit increasing 22% to INR198 crore. The company saw significant margin expansion, with gross margins up 200 bps to 69.1% and operating EBITDA margin at 28.7%. Domestic business outpaced the IPM with 10% growth, and international formulations grew 20%, though the CDMO segment remained flat. The company reiterated its FY26 operating margin guidance of 27-29% and expects continued outperformance in India and high single-digit growth internationally.

Highlights

  • Top line revenues grew 11% to INR1,065 crore, demonstrating strong performance.

  • Operating EBITDA, excluding noncash ESOP, increased 13% to INR305 crore.

  • Net profit rose significantly by 22% to INR198 crore.

  • Gross margins expanded by 200 bps to 69.1%, driven by attractive product mix and stable raw material costs.

  • Domestic business achieved 10% YoY growth to INR620 crore, outperforming the Indian Pharma Market (IPM) growth of 9% by 12%.

  • International formulation businesses recorded robust 20% YoY growth to INR306 crore, with strong performance in Russia, South Africa, and the U.S.

Concerns

  • The CDMO category remained nearly flat at INR117 crore for Q3 FY26, despite overall strong performance.

  • Management noted that March is generally a soft month for Indian pharmaceutical companies due to inventory closing from distributors, which could impact quarterly run rates.

  • A slowdown in the acute gastro business contributed to the domestic growth being closer to 10% instead of the 11-12% seen in other chronic portfolios.

Key financials

  1. Revenue ₹1,065 Cr +11%YoY
  2. Operating EBITDA (excl. ESOP) ₹305 Cr +13%YoY
  3. Net Profit ₹198 Cr +22%YoY
  4. Gross Margins 69.1% +2%YoY
  5. Operating EBITDA Margin 28.7% +0.6%YoY
  6. Other Income ₹18 Cr
  7. Depreciation ₹45 Cr

What they filed

Q4 FY26: revenue down 7.2%, net profit down 35.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue952 956 914 901 1,040 +9%1,023 +7%991 +8%836 −7%
EBITDA273 268 245 231 293 +7%298 +11%270 +10%195 −16%
Net profit173 173 156 150 198 +14%200 +16%179 +15%97 −35%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹1,509 Cr Total
  • Domestic Business ₹620 Cr 41.1%
  • International Business ₹445 Cr 29.5%
  • International Formulations ₹306 Cr 20.3%
  • CDMO ₹117 Cr 7.8%
  • API ₹21 Cr 1.4%

Capital allocation

high confidence
  • Debt Debt disclosed
    • Repayment All debt repaid, leading to surplus cash and higher treasury income.
    So it is basically because of the simple reason is that, since we have repaid all our debt, we had some opening debt in last year. And now we have repaid all our debt, and we have got surplus cash which we are investing as per our treasury policy, and that is resulting into higher treasury income.
  • M&A Torrent Merger · Pending regulatory
    It is a work in progress, and it is progressing at its on normal speed. And we will keep on updating as and when we have got any fresh development. ... the closure is expected in quarter 4 and the merger can happen any time, 6 to 9 months from there on.
  • Liquidity Liquidity disclosed Company has surplus cash due to debt repayment, which is being invested as per treasury policy, resulting in higher treasury income.
    And now we have repaid all our debt, and we have got surplus cash which we are investing as per our treasury policy, and that is resulting into higher treasury income.

Guidance & targets

Margin

  • Operating EBITDA Margin Margin · FY26 · High confidence 27% to 29%
    We reiterate our guidance for operating margins between 27% to 29% for FY '26.

    — Narayan Saraf

  • Gross Margin Margin · End of FY26 · Medium confidence 60% to 69%
    And our gross margin should reach between 60% to 69% by the end of the year.

    — Nikhil Chopra

Growth

  • Domestic Business Growth vs Market Growth · FY26 · High confidence 200 to 300 bps better than market
    our guidance continues to be growing better than the market 200 to 300 bps, which is in line to where we stand today, and that is how it will happen by the end of the year also.

    — Nikhil Chopra

  • CDMO Business Growth Growth · FY27 · High confidence 10% to 12%
    And you should expect us to grow at around 10% to 12% for FY '27.

    — Nikhil Chopra

  • International Business Growth Growth · End of FY26 · High confidence high single digit
    And what we guide for the year is we should grow at high single digit by the end of the year, and that is what we had shared in our quarter 2 commentary in the Investor call.

    — Nikhil Chopra

  • Ophthalmology Portfolio Growth Growth · FY26 · Medium confidence double-digit growth
    I think we will be double-digit growth in Opthal portfolio as well.

    — Kunal Khanna

Run Rate

  • Ophthalmology Portfolio Monthly Run Rate Run Rate · next 3 to 4 months · High confidence INR17 crore to INR18 crore per month
    we are well poised to reach our aspirations of having a consistent INR17 crore to INR18 crore per month run rate for this portfolio in the next 3 to 4 months.

    — Kunal Khanna

Expense

  • ESOP Charge Expense · Q4 FY26 · High confidence INR40 crore
    So assuming if the change of control event happens in quarter 4, then we are clearly looking at around INR40 crore of ESOP charge, whatever is balance leftover to be charged in the quarter 4.

    — Narayan Saraf

What to watch in Q4 FY26

Torrent Merger Status and Timeline

next quarter
Current Work in progress, closure expected in Q4 FY26
Target Closure announced in Q4 FY26, with integration timeline of 6-9 months post-closure

Why it matters

The merger with Torrent is a significant strategic event, and its closure and subsequent integration timeline will impact future business structure and performance.

the closure is expected in quarter 4 and the merger can happen any time, 6 to 9 months from there on.

Risks & concerns

  • Softness in Domestic Market during March

    medium

    March is typically a soft month for Indian pharma due to distributor inventory closing, which can impact quarterly run rates.

    Management acknowledged

  • Slowdown in Acute Gastro Business

    medium

    A slowdown in the acute gastro portfolio contributed to domestic growth being slightly lower than the chronic portfolio's performance.

    Management acknowledged

Q&A highlights

6 direct, 1 evasive
Domestic Price Hikes Direct
So if you really look at our numbers, we try to maximize the price hike. Our price hike generally for the quarter is in -- close to 7%.

Provides specific insight into the company's pricing strategy and contribution to revenue growth in the domestic market.

Asked by Sumit Gupta

Domestic Growth Guidance vs. Current Performance Direct
Yes, Sumit, if you look at our growth YTD 9 months for India business, which is close to around 11%, 12%, our guidance continues to be growing better than the market 200 to 300 bps, which is in line to where we stand today, and that is how it will happen by the end of the year also.

Clarifies that the company is on track with its domestic growth guidance, outperforming the market despite a slightly lower quarterly growth.

Asked by Sumit Gupta

Drivers of Margin Improvement Direct
So overall, if you look at the product mix, which is a combination of what we have done in India business with our chronic portfolio contributing on the higher side and our international business mix of CDMO business and what business we have done in some of the geographies that has led to better gross margins for the quarter.

Explains the key factors contributing to the improved gross and operating margins, highlighting the strategic product and business mix.

Asked by Sumit Gupta

Interim Dividend Policy Partial
Yes. So interim dividend, we have not announced yet. However, once the right time opportunity comes, we will inform and update you about the dividends.

Addresses analyst concern about the absence of an interim dividend, indicating a potential change in timing or policy without a definitive answer.

Asked by Pareen Parikh

Torrent Merger Timeline Direct
the closure is expected in quarter 4 and the merger can happen any time, 6 to 9 months from there on.

Provides a clearer timeline for the significant merger with Torrent, indicating potential completion within the next 6-9 months after Q4 closure.

Asked by Pareen Parikh

Synergies from Torrent Merger Evasive
We would not like to comment on any of the synergy situation as of now.

Management declined to provide details on potential synergies, leaving investors without specific insights into the strategic benefits of the merger.

Asked by Ananya Khanna

CDMO Revenue Run Rate and FY27 Growth Direct
this quarter was a base effect, but our run rate for the quarter for every quarter continues to be around INR115 crore to INR120 crore for this year. And you should expect us to grow at around 10% to 12% for FY '27.

Offers specific revenue run rate and future growth expectations for the CDMO business, providing clarity on this segment's outlook.

Asked by Abdulkader Puranwala

Impact of New Labour Law Code Direct
No very significant. We have taken the necessary impacts in our P&L, and it was not something substantial enough.

Reassures investors that the new labour law code has not had a substantial negative impact on the company's financials.

Asked by Abdulkader Puranwala

3 min read 7 chapters

Detailed narrative

Strong Financial Performance in Q3 FY26

J.B. Chemicals & Pharmaceuticals Limited reported robust financial results for Q3 FY26, with top line revenues growing 11% year-on-year to INR1,065 crore. Operating EBITDA, excluding noncash ESOP, increased by 13% to INR305 crore, while net profit saw a significant rise of 22% to INR198 crore. This strong performance was underpinned by a 200 bps expansion in gross margins to 69.1%, attributed to an attractive product mix, realized price improvements, and stable raw material costs. The operating EBITDA margin also improved by 60 bps year-on-year, reaching 28.7%.

Robust Domestic Business Growth Outperforming IPM

The domestic business segment demonstrated strong growth, achieving a 10% year-on-year increase to INR620 crore. According to IQVIA December MAT data, J.B. Pharma remains the fastest-growing company within the top 25 Indian pharma companies, outperforming the IPM growth of 9% with a 12% growth. The company's major brands continued to deliver strong growth, with six brands now featuring in the top 300 brands in the Indian pharma market. Management noted that the chronic portfolio contributed significantly to this growth, while some slowdown was observed in the acute gastro portfolio.

International Operations Momentum Driven by Formulations

International operations grew 12% year-on-year to INR445 crore in Q3 FY26. This growth was primarily driven by the international formulation businesses, which saw a 20% year-on-year revenue increase to INR306 crore. Strong performance was observed in key markets such as Russia, South Africa, and the U.S., as well as other branded export markets. The company expects to maintain this momentum, with a good order book for Q4, aiming for high single-digit growth for the full year in international markets.

CDMO Segment Performance and Outlook

The CDMO business maintained its momentum, though it remained nearly flat at INR117 crore in Q3 FY26, which was attributed to a high base in the prior year. Despite this, the company's focus on cost optimization, favorable product mix, and operational efficiencies led to improved operating margins for the segment. For FY27, the company expects the CDMO business to grow at a rate of 10% to 12%, with a consistent quarterly run rate of INR115 crore to INR120 crore for the current year.

Capital Structure and Enhanced Treasury Income

The company has successfully repaid all its debt, which was a key focus from the previous year. This debt repayment has resulted in the company holding surplus cash. This surplus cash is now being strategically invested as per the company's treasury policy, leading to a significant increase in other income. Other income for the quarter rose to INR18 crore, compared to INR8 crore in Q3 FY25, reflecting the positive impact of the improved liquidity position.

Update on Merger with Torrent and Future Outlook

The proposed merger with Torrent is currently a work in progress, proceeding at a normal pace. Management indicated that the closure of the merger is expected in Q4 FY26, with the integration process potentially taking an additional 6 to 9 months thereafter. The company reiterated its FY26 operating margin guidance of 27% to 29% and expects to continue outperforming the market in India while achieving high single-digit growth in international markets for the full year.

Ophthalmology Portfolio Growth and Run Rate Targets

The ophthalmology portfolio is expected to achieve double-digit growth. Management is poised to reach a consistent monthly run rate of INR17 crore to INR18 crore for this portfolio within the next 3 to 4 months. This focus on the ophthalmology segment is part of the company's strategy to drive growth and expand its presence in specialized therapeutic areas, complementing its strong chronic portfolio.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls